Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections.
【저자키워드】 viral infection, Influenza, Favipiravir, 【초록키워드】 SARS-CoV-2, coronavirus, therapy, SARS-COV-2 infection, Infection, Toxicity, Influenza virus, antiviral drug, Replication, Ebola virus disease, infections, Effectiveness, Japan, RdRP, RNA-dependent RNA polymerase, inhibitor, parameters, mechanism, pharmacokinetic, clinical study, antiviral therapies, adverse effect, acute respiratory syndrome, viral transcription, human RNA, approved, acting, FPV,